Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Impax, Perrigo In Generic Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Impax, Perrigo In Generic Development Pact

To manufacture and commercialize topical product

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Impax Laboratories and Perrigo have entered into a collaboration for the development, manufacture and commercialization of an undisclosed extended topical generic drug product. Financial terms were not disclosed.

“We are excited to expand our relationship with Perrigo on this product,” said Larry Hsu, Ph.D., president and chief executive officer of Impax Laboratories. In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of these either pending approval at the U.S. Food and Drug Administration or under development. We will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”

Perrigo’s chairman, president and chief executive officer Joseph C. Papa, said, “This collaboration is yet another example of our long-term investment in development of products in the extended topical space. We are pleased to be partnering with Impax on this opportunity to be first to market with this important new product, making quality healthcare more affordable for our customers as quickly as possible.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters